Synergistic effect of cisplatin chemotherapy combined with fractionated radiotherapy regimen in HPV-positive and HPV-negative experimental pharyngeal squamous cell carcinoma

Scientific Reports - Tập 10 Số 1
Simona Kranjc1, Ajda Prevc1, Martina Nikšić Žakelj1, Andreja Brožič2, Maja Čemažar1, Primož Strojan3, Gregor Serša4
1Department of Experimental Oncology, Institute of Oncology Ljubljana, SI-1000, Ljubljana, Slovenia
2Department of Cytology and Pathology, Institute of Oncology Ljubljana, SI-1000, Ljubljana, Slovenia
3Department of Radiation Oncology, Institute of Oncology Ljubljana, SI-1000, Ljubljana, Slovenia
4Faculty of Health Sciences, University of Ljubljana, SI-1000 Ljubljana, Slovenia

Tóm tắt

AbstractHPV infection renders oropharyngeal squamous cell carcinomas more radiosensitive, which results in a favorable prognosis for HPV-positive patients treated with radiation alone or with concurrent platinum-based chemotherapy. The degree of radiosensitivity in fractionated regimens has not yet been fully explored; therefore, in this study, the radiosensitivity of HPV-negative tumors (FaDu) was compared to that of HPV-positive tumors (2A3) subjected to concurrent cisplatin chemotherapy and fractionated versus isoeffective single-dose tumor irradiation in immunodeficient mice. HPV-positive tumors were approximately 5 times more radiosensitive than HPV-negative tumors, irrespective of the irradiation regimen. In both tumor models, concurrent cisplatin chemotherapy and the fractionated regimen induced significant tumor radiosensitization, with a 3- to 4-fold increase in the tumor growth delay compared to that of single-dose irradiation. Furthermore, the degree of radiosensitization induced by cisplatin chemotherapy concurrent with the fractionated irradiation regimen was much higher in HPV-positive tumors, where a synergistic antitumor effect was observed. Specifically, after combined therapy, a 26% higher survival rate was observed in mice with HPV-positive tumors than in mice with HPV-negative tumors. These data suggest that HPV-positive tumors are more radiosensitive to fractionated regimen than to single-dose irradiation with concurrent cisplatin chemotherapy acting synergistically to irradiation.

Từ khóa


Tài liệu tham khảo

Marur, S., D’Souza, G., Westra, W. H. & Forastiere, A. A. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 11, 781–789 (2010).

Ang, K. K. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363, 24–35 (2010).

O’Sullivan, B. et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J. Clin. Oncol. 31, 543–550 (2013).

Arenz, A. et al. Increased radiosensitivity of HPV-positive head and neck cancer cell lines due to cell cycle dysregulation and induction of apoptosis. Strahlenther Onkol. 190, 839–846 (2014).

Kimple, R. J. et al. Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res. 73, 4791–4800 (2013).

Prevc, A. et al. Dose-modifying factor of radiation therapy with concurrent cisplatin treatment in HPV-positive squamous cell carcinoma: a preclinical study. Radiat. Res. 189, 644–651 (2018).

Rieckmann, T. et al. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother. Oncol. 107, 242–246 (2013).

Ziemann, F. et al. Increased sensitivity of HPV-positive head and neck cancer cell lines to x-irradiation ± Cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis. Am. J. Cancer Res. 107, 1017–1031 (2015).

Gillison, M. L. et al. Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. J. Clin. Oncol. 27, 6003 (2009).

Fakhry, C. et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Inst. 100, 261–269 (2008).

Münger, K. et al. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78, 11451–11460 (2004).

Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129–1136 (1990).

Münger, K. et al. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8, 4099–4105 (1989).

Vu, H. L., Sikora, A. G., Fu, S. & Kao, J. HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett. 288, 149–155 (2010).

Marur, S. et al. E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN cancer research group. J. Clin. Oncol. 35, 490–497 (2017).

Seiwert, T. Y. et al. Optima: A phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann. Oncol. 30, 297–302 (2019).

Chen, A. M. et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol. 18, 803–811 (2017).

Harris, M. et al. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line. Head Neck Oncol. 3, 9 (2011).

Otto, F. DAPI Staining of Fixed Cells for high-resolution flow cytometry of nuclear DNA. Methods Cell Biol. 33, 105–110 (1990).

Wheldon, T. E., Deehan, C., Wheldon, E. G. & Barrett, A. The linear-quadratic transformation of dose-volume histograms in fractionated radiotherapy. Radiother. Oncol. 46, 285–295 (1998).

Spector, S. A., Tyndall, M. & Kelley, E. Effects of acyclovir combined with other antiviral agents on human cytomegalovirus. Am. J. Med. 73, 36–39 (1982).

Kaplan, E. L. & Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457–481 (1958).

Peto, R. et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer 35, 1–39 (1977).

Dalianis, T. Human papillomavirus and oropharyngeal cancer, the epidemics, and significance of additional clinical biomarkers for prediction of response to therapy (Review). Int. J. Oncol. 44, 1799–1805 (2014).

Mirghani, H. & Blanchard, P. Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand? Clin. Transl. Radiat. Oncol. 8, 4–11 (2018).

Spanos, W. C. et al. Immune response during therapy with cisplatin or radiation for human papillomavirus–related head and neck cancer. Arch. Otolaryngol. Neck Surg. 135, 1137–1146 (2009).

Nagel, R. et al. Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines. Oral Oncol. 49, 560–566 (2013).

Marullo, R. et al. HPV16 E6 and E7 proteins induce a chronic oxidative stress response via NOX2 that causes genomic instability and increased susceptibility to DNA damage in head and neck cancer cells. Carcinogenesis 36, 1397–1406 (2015).

Dok, R. & Nuyts, S. HPV positive head and neck cancers: Molecular pathogenesis and evolving treatment strategies. Cancers (Basel). 8, (41 (2016).

Williams, V. M., Filippova, M., Filippov, V., Payne, K. J. & Duerksen-Hughes, P. Human papillomavirus type 16 E6* induces oxidative stress and DNA damage. J. Virol. 88, 6751–6761 (2014).

Göttgens, E. L., Ostheimer, C., Span, P. N., Bussink, J. & Hammond, E. M. HPV, hypoxia and radiation response in head and neck cancer. Br. J. Radiol., 20180047, https://doi.org/10.1259/bjr.20180047 (2018).

Pawlik, T. M. & Keyomarsi, K. Role of cell cycle in mediating sensitivity to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59, 928–942 (2004).

Hall, E. J. & Cox, J. D. Physical and biologic basis of radiation therapy in radiation oncology (ed. Cox, J. D., Ang, K. K.) 3–49 (Elsevier Inc., 2016).

Busch, C. J. et al. Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines. Oncotarget 7, 35832–35842 (2016).

Blanchard, P. et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother. Oncol. 100, 33–40 (2011).

Pignon, J.-P., Maître, A., le, Maillard, E. & Bourhis, J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother. Oncol. 92, 4–14 (2009).

Yip, H. T. et al. Cisplatin-induced growth arrest of head and neck cancer cells correlates with increased expression of p16 and p53. Arch. Otolaryngol. Neck Surg. 132, 317–326 (2006).

Mikulandra, M., Kobescak, A., Verillaud, B., Busson, P. & Matijevic Glavan, T. Radio-sensitization of head and neck cancer cells by a combination of poly(I:C) and cisplatin through downregulation of survivin and c-IAP2. Cell. Oncol. 42, 29–40 (2019).

Sandulache, V. C. et al. Metabolic interrogation as a tool to optimize chemotherapeutic regimens. Oncotarget 8, 18154–18165 (2017).

Demaria, S. & Formenti, S. C. Role of T lymphocytes in tumor response to radiotherapy. Front. Oncol. 2, 95 (2012).

Golden, E. B. & Apetoh, L. Radiotherapy and immunogenic cell death. Semin. Radiat. Oncol. 25, 11–17 (2015).

De Biasi, A. R., Villena-Vargas, J. & Adusumilli, P. S. Cisplatin-induced antitumor immunomodulation: A review of preclinical and clinical evidence. Clin. Cancer Res. 20, 5384–5391 (2014).

Kulzer, L. et al. Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells. J. Immunotoxicol. 11, 328–336 (2014).

Demaria, S. et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58, 862–870 (2004).

Demaria, S., Golden, E. B. & Formenti, S. C. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 1, 1325–1332 (2015).

Demaria, S. et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11, 728–734 (2005).

Meshman, J. et al. Immunologic mediators of outcome for irradiated oropharyngeal carcinoma based on human papillomavirus status. Oral Oncol. 89, 121–126 (2019).

Wieking, B. G. et al. A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. Cancer Gene Ther. 19, 667–674 (2012).

Lee, D. W., Anderson, M. E., Wu, S. & Lee, J. H. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus–positive cancer. Arch. Otolaryngol. Neck Surg. 134, 1316–1323 (2008).

Vermeer, D. W. et al. Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer. Int. J. Cancer 133, 120–129 (2013).

Klug, F. et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24, 589–602 (2013).

Welters, M. J. P. et al. Intratumoral HPV16-specific T cells constitute a type I–oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer. Clin. Cancer Res. 24, 634–647 (2018).

Thông tin
Thông tin xuất bản

Scientific Reports

Tập 10 Số 1

Thông tin tác giả